SPY313.78-3.27 -1.03%
DIA259.04-3.96 -1.51%
IXIC10,343.89-89.76 -0.86%

Oppenheimer Maintains Outperform on UroGen Pharma, Lowers Price Target to $52

Oppenheimer maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from $62 to $52.

Benzinga · -

Oppenheimer maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from $62 to $52.